Pivotal Therapeutics Inc. (PVTTF) Research

Pivotal Therapeutics Inc. is a specialized pharmaceutical firm primarily dedicated to addressing cardiovascular ailments and promoting general well-being. The company's flagship offering, VASCAZEN, is a medical food available by prescription only. It's specifically designed for the clinical dietary intervention of cardiovascular disease in individuals diagnosed with coronary heart disease who also exhibit low levels of Omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in their bloodstream. Furthermore, Pivotal Therapeutics markets OMAZEN, which aims to support general health by boosting Omega-3 fatty acid concentrations. Its Benefishial product line is under development, targeting a wide range of health needs such as comprehensive well-being, heart health, maternal and fetal health, and specific formulations for toddlers, children, and even pets. A significant pipeline asset, PVT-100, is being developed to stabilize fragile plaque formations in patients undergoing carotid endarterectomy. Currently, VASCAZEN is distributed within the United States, while OMAZEN is sold in Canada. The corporate headquarters for Pivotal Therapeutics Inc. are situated in Woodbridge, Canada.

Open Pivotal Therapeutics Inc. (PVTTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.